Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model.

Peripheral-blood mononuclear cells (PBMCs) mobilized with AMD3100, a CXCR4 antagonist, combined with granulocyte colony-stimulating factor (G-CSF) have reconstituted autologous hematopoiesis in cancer patients following myeloablative conditioning. The engraftment potential of PBMCs mobilized with AMD3100 alone, however, has remained unproven. We therefore studied AMD3100-mobilized PBMCs in a canine model. Four dogs received 920 cGy total body irradiation (TBI) before infusion of autologous AMD3100-mobilized PBMCs (median CD34 cell count, 3.9 x 10(6)/kg). Neutrophil (> 0.5 x 10(9)/L [500/microL]) and platelet (> 20 x 10(9)/L [> 20 000/microL]) recoveries occurred at medians of 9 (range, 7-10) days and 25 (range, 23-38) days, respectively, after TBI, and all dogs had normal marrow function at 1 year after transplantation. To evaluate the long-term engraftment potential of AMD3100-mobilized PBMCs, 5 dogs were given 920 cGy TBI followed by infusion of AMD3100-mobilized PBMCs (median CD34 cell dose, 4.7 x 10(6)/kg) from their dog leukocyte antigen (DLA)-identical littermates. Neutrophil and platelet recoveries occurred at medians of 8 (range, 8-10) days and 26 (range, 26-37) days, respectively, after TBI. With a median follow-up of 53 (range, 33-61) weeks, recipients' marrow function was normal, and blood-donor chimerism levels were 97% to 100%. In summary, both autologous and allogeneic AMD3100-mobilized PBMCs led to prompt and durable engraftment in dogs after 920 cGy TBI.

[1]  J. Dipersio,et al.  The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. , 2005, Blood.

[2]  M. Sorror,et al.  What Role Is There for Antithymocyte Globulin in Allogeneic Nonmyeloablative Canine Hematopoietic Cell Transplantation? , 2005, Biology of Blood and Marrow Transplantation.

[3]  Christie M. Orschell,et al.  Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist , 2005, The Journal of experimental medicine.

[4]  F. Petersen,et al.  Effect of prior chemotherapy on hematopoietic stem cell mobilization , 2004, Bone Marrow Transplantation.

[5]  J. Dipersio,et al.  Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Mette M. Rosenkilde,et al.  Molecular Mechanism of AMD3100 Antagonism in the CXCR4 Receptor , 2004, Journal of Biological Chemistry.

[7]  R. Storb,et al.  Identification and characterization of a highly polymorphic microsatellite marker within the canine MHC Class I region , 1995, Mammalian Genome.

[8]  B. Wood,et al.  Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. , 2003, Blood.

[9]  T. Papayannopoulou,et al.  The role of G-protein signaling in hematopoietic stem/progenitor cell mobilization. , 2003, Blood.

[10]  J. Lévesque,et al.  Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. , 2003, The Journal of clinical investigation.

[11]  A. Nagler,et al.  Human CD34(+)CXCR4(-) sorted cells harbor intracellular CXCR4, which can be functionally expressed and provide NOD/SCID repopulation. , 2002, Blood.

[12]  R. Taichman,et al.  G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4 , 2002, Nature Immunology.

[13]  W. Chan,et al.  Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  R. Storb,et al.  G-CSF-mobilized peripheral blood mononuclear cells added to marrow facilitates engraftment in nonmyeloablated canine recipients: CD3 cells are required. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  R. Storb,et al.  Hematopoietic responses to stress conditions in young dogs compared with elderly dogs. , 2001, Blood.

[16]  S. Rafii,et al.  Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. , 2001, Blood.

[17]  R Storb,et al.  Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. , 2001, The New England journal of medicine.

[18]  J. D. Thompson,et al.  Adoptive immunotherapy in canine mixed chimeras after nonmyeloablative hematopoietic cell transplantation. , 2000, Blood.

[19]  J. Bourhis,et al.  Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  R. Alon,et al.  Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. , 1999, Science.

[21]  F. Aranha,et al.  A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies , 1998, Bone Marrow Transplantation.

[22]  R. Storb,et al.  DLA-DRB1 and DLA-DQB1 histocompatibility typing by PCR-SSCP and sequencing. , 1998, Tissue antigens.

[23]  S. Rafii,et al.  Transendothelial Migration of Megakaryocytes in Response to Stromal Cell-derived Factor 1 (SDF-1) Enhances Platelet Formation , 1998, The Journal of experimental medicine.

[24]  Zhong-ying Liu,et al.  The α-Chemokine Receptor CXCR4 Is Expressed on the Megakaryocytic Lineage From Progenitor to Platelets and Modulates Migration and Adhesion , 1998 .

[25]  S. Rafii,et al.  The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. , 1998, Blood.

[26]  N. Schmitz,et al.  Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation , 1998, Bone Marrow Transplantation.

[27]  H. Deeg,et al.  Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts. , 1998, Blood.

[28]  R. Storb,et al.  Characterization of monoclonal antibodies that recognize canine CD34. , 1998, Blood.

[29]  H. Deeg,et al.  Dose rate-dependent sparing of the gastrointestinal tract by fractionated total body irradiation in dogs given marrow autografts. , 1998, International journal of radiation oncology, biology, physics.

[30]  G. Molineux,et al.  Flt-3 ligand synergizes with granulocyte colony-stimulating factor to increase neutrophil numbers and to mobilize peripheral blood stem cells with long-term repopulating potential. , 1997, Blood.

[31]  H. Deeg,et al.  Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. , 1997, Blood.

[32]  T. Springer,et al.  The Chemokine SDF-1 Is a Chemoattractant for Human CD34+ Hematopoietic Progenitor Cells and Provides a New Mechanism to Explain the Mobilization of CD34+ Progenitors to Peripheral Blood , 1997, The Journal of experimental medicine.

[33]  E. Ostrander,et al.  Histocompatibility testing of dog families with highly polymorphic microsatellite markers. , 1996, Transplantation.

[34]  H. Deeg,et al.  Allogeneic transplants of canine peripheral blood stem cells mobilized by recombinant canine hematopoietic growth factors , 1996 .

[35]  J. Armitage,et al.  Phase I/II trial of PIXY321 to enhance engraftment following autologous bone marrow transplantation for lymphoid malignancy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  C. McFarland,et al.  Quantitative determination of bone marrow transplant engraftment using fluorescent polymerase chain reaction primers for human identity markers. , 1995, Blood.

[37]  E. Bryant,et al.  USE OF (CA)n POLYMORPHISMS TO DETERMINE THE ORIGIN OF BLOOD CELLS AFTER ALLOGENEIC CANINE MARROW GRAFTING , 1994, Transplantation.

[38]  R. Andrews,et al.  Effects of granulocyte colony-stimulating factor and stem cell factor, alone and in combination, on the mobilization of peripheral blood cells that engraft lethally irradiated dogs. , 1994, Blood.

[39]  P. Bierman,et al.  Long-term follow-up of a phase III study of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid malignancies. , 1993, Blood.

[40]  J. Singer,et al.  Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. , 1993, Blood.

[41]  D. Danilenko,et al.  Monoclonal antibodies specific for canine CD4 and CD8 define functional T-lymphocyte subsets and high-density expression of CD4 by canine neutrophils. , 1992, Tissue antigens.

[42]  L. To,et al.  Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. , 1992, Bone marrow transplantation.

[43]  G. Kandel,et al.  Comparison of hematopoietic and immune recovery after autologous bone marrow or blood stem cell transplants. , 1992, Bone marrow transplantation.

[44]  W. Fibbe,et al.  Recombinant human granulocyte-macrophage colony-stimulating factor accelerates neutrophil and monocyte recovery after allogeneic T-cell-depleted bone marrow transplantation. , 1992, Blood.

[45]  J. Armitage,et al.  Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. , 1991, The New England journal of medicine.

[46]  R. Bast,et al.  Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. , 1988, The New England journal of medicine.

[47]  J. E. Walsh,et al.  Contributions to the Theory of Rank Order Statistics--The Two Sample Case , 1958 .